Aditya Birla, an Indian multinational conglomerate, recently announced the expansion of its US Advanced Materials business with the acquisition of Cargill’s specialty chemical facility in Dalton, Georgia.
Brenntag recently announced the acquisition of Mcepharma to strengthen Brenntag’s capabilities across the entire pharmaceutical and biopharmaceutical value chain.
Dow announced that it has signed a sale and purchase agreement to sell its 50% interest in DowAksa to Aksa Akrilik Kimya Sanayii A.Ş., a company of Akkök Holding.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology.
BASF and DOMO Chemicals have signed an agreement giving BASF the right to acquire DOMO Chemicals' 49% stake in the Alsachimie joint venture, in which BASF currently holds 51%.
Sanofi to acquire Vigil Neuroscience, a clinical-stage biotech focused on therapies for neurodegenerative diseases.
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
IMCD has signed an agreement to acquire 100% of the shares in Tecom Ingredients.
Sojitz, Sumitomo Chemical, and Mitsui Chemicals have concluded a share purchase agreement in which Sojitz will acquire Nippon A&L.
PCI Pharma Services has completed its acquisition of Ajinomoto Althea, a CDMO subsidiary of Ajinomoto.
Roquette completes IFF Pharma Solutions acquisition and unveils new structure for global growth and innovation.
Merck and biopharmaceutical company SpringWorks Therapeutics, have entered into a definitive agreement for Merck to acquire SpringWorks.
Strategic Value Partners (SVP) and Blantyre Capital Limited (Blantyre) recently announced the acquisition of OQ Chemicals (Oxea), a leading global producer and merchant of oxo chemicals.
HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
The completion of the deal marks the third major investment by Ineos Energy in the USA in the past three years. It increases Ineos' capital spending on energy assets in the USA to above $3 billion.
Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.
Rio Tinto has completed the $6.7 billion acquisition of Arcadium Lithium and is now the parent company of Arcadium Lithium, which will be renamed Rio Tinto Lithium and will also include the Rincon Lithium Project.
Ireland’s Jazz Pharmaceuticals signed an agreement to acquire its compatriot Chimerix for approximately $935 million. The transaction is expected to close in the second quarter of 2025.
OMV and ADNOC agreed to combine their Borealis and Borouge shareholdings into Borouge Group International. ADNOC has also signed a share purchase agreement with Nova Chemicals, an indirect wholly owned subsidiary of Mubadala Investment Company, to acquire 100% of Nova Chemicals for an enterprise value of $13.4 billion. In addition, ADNOC and OMV have agreed for Borouge Group International to take over Nova Chemicals after closing.
WE Soda has acquired Genesis Alkali (Alkali), the largest US-based producer of natural soda ash, from Genesis Energy in an all-cash transaction for $1.425 billion.
Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed.
US investment company Pritzker Private Capital (PPC) has agreed to acquire a majority stake in Americhem, a family-owned US manufacturer of custom color masterbatch, performance additive and engineered compound solutions.
US-based biotechnology company FibroGen announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.
Following completion of the required social and corporate procedures, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).
Novonesis has reached an agreement with its partner DSM-Firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, for a total cash payment of €1.5 billion. The transaction is subject to customary closing conditions.
Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
US private equity company Bain Capital has agreed to acquire Mitsubishi Tanabe Pharma Corp. (MTPC) from Mitsubishi Chemical Group Corp. in a deal that values the business at approximately 510 billion Japanese yen ($3.3 billion).
Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing. Financial details of the transaction, which was completed on Feb. 3, 2025, were not given.
Sage Therapeutics announced that its board of directors has unanimously rejected the proposal it received from Biogen on Jan. 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, representing an equity value of about $469 million.
Johnson & Johnson and Intra-Cellular Therapies recently entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.
Grupa Azoty and Orlen have agreed to continue to work on the terms of a potential transaction whereby Orlen – or another entity designated by Orlen – would acquire all or a portion of the shares currently held by Grupa Azoty in Grupa Azoty Polyolefins or otherwise execute the investment.
Barentz, a global specialty ingredients provider, recently announced the acquisition of NCD Ingredients, a specialty, personal, and home care ingredients distributor active in Germany, Austria, and Switzerland (DACH). The acquisition enhances Barentz’s presence in the DACH region, with a particular focus on Germany—the second-largest personal care market in EMEA.
IMCD, a global distribution and formulation partner of specialty chemicals and ingredients, has agreed to acquire the personal care and pharmaceutical business of YCAM, a distributor based in South Korea.
In a move to expand its oncology business, GSK is nearing a $1 billion deal to buy a US biotech developing a treatment for rare gastrointestinal tumors.
Ashland recently announced that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
